Toll free

18002022232

Therapies

What is TCR Therapy?

TCR (T - cell Receptor) Therapy is a form of Immunotherapy that involves genetically modifying a patient’s T - cells to express receptors specifically designed to recognize and target cancer cells.

How does T - cell Receptor (TCR) Therapy work?

  1. Collection: T ‐ cells are collected from the patient through a biopsy as the first step of the TCR process.
  2. Modification: In the laboratory, the collected T ‐ cells are genetically modified to express T-cell receptors (TCRs) that are specific to antigens found on the patient’s cancer cells.
  3. Expansion: The modified T ‐ cells are then expanded in number to increase their effectiveness.
  4. Infusion: The expanded T ‐ cells are infused back into the patient’s bloodstream.
  5. Targeting Cancer: These TCR-engineered cells seek out and destroy cancer cells that express the specific antigens.

Benefits

Targeted Approach: TCRs can be engineered to target specific cancer antigens, providing a highly focused treatment.

Potential for High Efficacy: By directing T - cells to attack cancer cells with specific antigens, TCR Therapy can lead to significant tumor reduction.

Adaptability: TCRs can be designed to target a wide range of cancer antigens, making the therapy applicable to various cancers.

SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male